T-Cell Lymphomas：グローバル臨床試験動向（2014年上半期）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
T-Cell Lymphomas 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of T-Cell Lymphomas to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of T-Cell Lymphomas to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of T-Cell Lymphomas 25
Subjects Recruited Over a Period of Time 30
Clinical Trials by Sponsor Type 31
Prominent Sponsors 32
Top Companies Participating in T-Cell Lymphomas Therapeutics Clinical Trials 33
Prominent Drugs 35
Latest Clinical Trials News on T-Cell Lymphomas 36
Dec 06, 2013: Rhizen Pharmaceuticals announces initiation of a “First in Human” Phase-1 trial of RP6530, a dual PI3K delta/gamma inhibitor, in patients with hematological malignancies 36
Jan 24, 2013: Seattle Genetics And Millennium Initiate Global Phase III Clinical Trial Of Adcetris In Front-line CD30-Expressing Mature T-Cell Lymphoma 36
Dec 10, 2012: Infinity Pharma Reports IPI-145 Phase I Data Showing Clinical Activity In B-Cell And T-Cell Malignancies At ASH Annual Meeting 37
Dec 09, 2012: Millennium And Takeda Report Data From Phase I Trial Of Adcetris In Front-line Mature T-Cell Lymphomas 39
May 07, 2012: Millennium And Seattle Initiate Phase III Trial Of ADCETRIS In Patients With CD30-Expressing Relapsed Cutaneous T-cell Lymphoma 40
Clinical Trial Profiles 42
Clinical Trial Overview of Top Companies 42
Seattle Genetics, Inc. 42
Clinical Trial Overview of Seattle Genetics, Inc. 42
Celgene Corporation 44
Clinical Trial Overview of Celgene Corporation 44
Takeda Pharmaceutical Company Limited 46
Clinical Trial Overview of Takeda Pharmaceutical Company Limited 46
Spectrum Pharmaceuticals, Inc. 48
Clinical Trial Overview of Spectrum Pharmaceuticals, Inc. 48
Amgen Inc. 49
Clinical Trial Overview of Amgen Inc. 49
Kirin Holdings Company, Limited 50
Clinical Trial Overview of Kirin Holdings Company, Limited 50
Bayer AG 51
Clinical Trial Overview of Bayer AG 51
Eisai Co., Ltd. 52
Clinical Trial Overview of Eisai Co., Ltd. 52
Infinity Pharmaceuticals, Inc. 53
Clinical Trial Overview of Infinity Pharmaceuticals, Inc. 53
Clinical Trial Overview of Top Institutes / Government 54
National Cancer Institute 54
Clinical Trial Overview of National Cancer Institute 54
Fred Hutchinson Cancer Research Center 59
Clinical Trial Overview of Fred Hutchinson Cancer Research Center 59
The University of Texas M. D. Anderson Cancer Center 62
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 62
Samsung Medical Center 63
Clinical Trial Overview of Samsung Medical Center 63
Sun Yat-sen University 64
Clinical Trial Overview of Sun Yat-sen University 64
FUDAN University 65
Clinical Trial Overview of FUDAN University 65
University of Nebraska 66
Clinical Trial Overview of University of Nebraska 66
Memorial Sloan Kettering Cancer Center 67
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 67
University of Washington 68
Clinical Trial Overview of University of Washington 68
Children’s Oncology Group 69
Clinical Trial Overview of Children’s Oncology Group 69
Five Key Clinical Profiles 70
Appendix 101
Abbreviations 101
Definitions 101
Research Methodology 102
Secondary Research 102
About GlobalData 103
Contact Us 103
Disclaimer 103
Source 104